Evidence map›Paper›PMID 35184139›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2022

MicroRNA-483-5p accentuates cisplatin-induced acute kidney injury by targeting GPX3.

Ying Xia, Wenbin Pan, Xiao Xiao, Xuejuan Zhou, Wenqing Gu, Yaqin Liu, Yanyan Zhao, Lixia Li, Chenghao Zheng, Jun Liu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Advances in the role of GPX3 in ovarian cancer (Review).International journal of oncology · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Prognostic value and immunological roles of GPX3 in gastric cancer.International journal of medical sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ying XiaDepartment of Cell biology, School of Basic Medical Science, Southern Medical University, Guangzhou, PR China.ORCID http://orcid.org/0000-0002-5066-7407
Wenbin PanDepartment of Cell biology, School of Basic Medical Science, Southern Medical University, Guangzhou, PR China.
Xiao XiaoDepartment of Cell biology, School of Basic Medical Science, Southern Medical University, Guangzhou, PR China.
Xuejuan ZhouDepartment of Cell biology, School of Basic Medical Science, Southern Medical University, Guangzhou, PR China.
Wenqing GuDepartment of Cell biology, School of Basic Medical Science, Southern Medical University, Guangzhou, PR China.
Yaqin LiuDepartment of Cell biology, School of Basic Medical Science, Southern Medical University, Guangzhou, PR China.
Yanyan ZhaoDepartment of Cell biology, School of Basic Medical Science, Southern Medical University, Guangzhou, PR China.
Lixia LiDepartment of Oncology, Southern Theater Command General Hospital of PLA, Guangzhou, PR China.
Chenghao ZhengSchool of Medicine, Shanghai JiaoTong University, Shanghai, PR China.
Jun LiuDepartment of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, PR China. liujun1980s@126.com.
Ming LiDepartment of Cell biology, School of Basic Medical Science, Southern Medical University, Guangzhou, PR China. looselj@smu.edu.cn.ORCID http://orcid.org/0000-0002-2778-2327
Southern Medical University · CNGeneral Hospital of Guangzhou Military Command · CNShanghai Jiao Tong University · CNZhujiang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ability of cisplatin (cis-diamminedichloroplatinum II) toxicity to induce acute kidney injury (AKI) has attracted attention and concern for a long time, but the molecular mechanism of action for cisplatin is not clear. MicroRNA-483 is involved in several diseases, such as tumorigenesis and osteoarthritis, but its renal target and potential role in AKI are unknown. In this study, we explored the pathogenic role and underlying mechanism of miR-483-5p in cisplatin-induced AKI, using transgenic mice, clinical specimen, and in vitro cell line. We found that miR-483-5p was significantly upregulated by cisplatin in a cisplatin-induced mouse model, in serum samples of patients who received cisplatin therapy, and in NRK-52E cells. Overexpression of miR-483-5p in mouse kidneys by stereotactic renal injection of lentiviruses mediated miR-483-5p or generation of conditional miR-483-overexpressing transgenic mice accentuated cisplatin-induced AKI by increasing oxidative stress, promoting apoptosis, and inhibiting autophagy of tubular cells. Furthermore, our results revealed miR-483-5p directly targeted to GPX3, overexpression of which rescued cisplatin-induced AKI by inhibiting oxidative stress and apoptosis of tubular cells, but not by regulating autophagy. Collectively, miR-483-5p is upregulated by cisplatin and exacerbates cisplatin-induced AKI via negative regulation of GPX3 and contributing oxidative stress and tubular cell apoptosis. These findings reveal a pathogenic role for miR-483-5p in cisplatin-induced AKI and suggest a novel target for the diagnosis and treatment of AKI.

Indexed as

Acute Kidney InjuryMicroRNAsAnimalsApoptosisCisplatinEpithelial CellsGlutathione PeroxidaseHumansKidneyMiceCisplatinGlutathione PeroxidaseGPX3 protein, humanMicroRNAsMIRN483 microRNA, human

Identifiers

PMID35184139
OpenAlexW4212898292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.